Lv6
2010 积分 2024-08-09 加入
Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial
1个月前
已完结
Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study
1个月前
已关闭
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial
3个月前
已完结
A0851 Treatment outcomes of enfortumab vedotin plus pembrolizumab in lymph node–positive urothelial carcinoma patients fit for cystectomy: Real-world data from an enfortumab registry
3个月前
已完结
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
4个月前
已完结
Higher blood–brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography
5个月前
已关闭
Real world efficacy and safety of ivosidenib in US veterans with IDH1 mutated cholangiocarcinoma
7个月前
已完结
262MO Preliminary efficacy outcomes of ivosidenib in patients with IDH1-mutated cholangiocarcinoma (mIDH1 CCA): Initial results from the phase IIIb ProvIDHe study
7个月前
已关闭
Final Results from a First-in-Human Phase 1 Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations
8个月前
已完结
皖公网安备34019202002308
